Upcoming NICE drug appraisal on elacestrant (Korserdu)

What’s the project about?

Elacestrant (brand name Korserdu) is a newly developed drug. NICE (the body that decides whether drugs should be made available on the NHS in England) is currently assessing the drug for treating certain people with hormone receptor positive, secondary breast cancer after a prior hormone treatment.

This appraisal will determine if it will be made available on the NHS in England.

Breast Cancer Now will be submitting a response to be considered as part of the appraisal. We’re looking for people who have received this drug (perhaps as part of a clinical trial) to share their experiences so that we can include these in our response.

Who can take part?

People with ER-positive, HER2-negative secondary breast cancer with an ESR1 mutation who have received the treatment elacestrant (Korserdu)

Why do you want me to be involved?

We want to represent the voices of people with breast cancer and ensure that their perspective is heard as part of this NICE appraisal. Your experiences and views can have a powerful effect on decision-makers.

What will you ask me to do?

We’d like to ask you some questions about your experience with breast cancer, your experience with this treatment, and what impact it could have if the treatment was made available to more patients.

You can choose to answer the questions via phone or email.

We’ll ask for your permission to include quotes from your answers in our submission to NICE and your name will not be shared.